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Abstract
Background: Vascular dementia is a common disorder resulting in considerable morbidity and mortality.
Determining the extent to which genes play a role in disease susceptibility and their pathophysiological
mechanisms could improve our understanding of vascular dementia, leading to a potential translation of this
knowledge to clinical practice.
Discussion: In this review, we discuss what is currently known about the genetics of vascular dementia. The
identification of causal genes remains limited to monogenic forms of the disease, with findings for sporadic
vascular dementia being less robust. However, progress in genetic research on associated phenotypes, such as
cerebral small vessel disease, Alzheimer’s disease, and stroke, have the potential to inform on the genetics of
vascular dementia. We conclude by providing an overview of future developments in the field and how such work
could impact patients and clinicians.
Conclusion: The genetic background of vascular dementia is well established for monogenic disorders, but remains
relatively obscure for the sporadic form. More work is needed for providing robust findings that might eventually
lead to clinical translation.
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Background
While vascular dementia (VaD) is the second most
common form of dementia [1], studies on its genetic
basis are scarce. It is well established that the risk of
VaD can be modified by various lifestyle factors, physio-
logical risk factors, and comorbidities [1]. However, its
genetic component remains poorly understood, espe-
cially when compared to other causes of dementia such
as Alzheimer’s disease (AD), Parkinson’s disease, and
frontotemporal lobar degeneration. Only a single study
in 24 twins has attempted to determine the heritability of
VaD, but was unable to identify a significant genetic com-
ponent [2]. While this could suggest that the environment
plays a larger role, a careful interpretation is warranted
given the limited sample size and the heterogeneity in
VaD definitions. Furthermore, several lines of evidence
actually indicate that VaD might have a substantial genetic
component.
In this review, we summarize the current knowledge
of the genetics of VaD and provide an overview of future
developments in genetic research on VaD. Besides the
diagnosis of VaD, we extend our report to include
several associated phenotypes, including AD and stroke,
as well as cerebral small vessel disease (CSVD), which
can be considered as a precursor or a distinct form of
VaD (see dedicated consensus report in this volume [3]).
These have all been shown to be significantly heritable
and to potentially share predisposing genetic factors.
This review builds on the 9th International Congress
on Vascular Dementia (ICVD), which took place in
Ljubljana, Slovenia, on 16–18 October 2015. The ICVD
meeting was structured in several Working Groups that
focused on specific topics within the field of VaD. The
current report is based on the work of the ‘Genetics of
Vascular Dementia’ Working Group.
Here, we provide a narrative review on the genetic as-
pect of VaD. First, we provide an overview of monogenic
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disorders that results in VaD. Second, we review our
current knowledge of the genetic background of spor-
adic VaD, which remains obscure. Third, we point to
future developments in the field that are likely to shed
light on the role of genetics. Finally, we discuss how a




The most apparent evidence for a genetic basis of VaD
is the fact that dysfunction of single genes can lead to
the development of VaD. Several of these monogenic
disorders have been described and are summarized in
Table 1, along with their clinical and neuroimaging
features relevant to VaD. Below, we highlight the most
important monogenic disorders.
A well-known monogenic disorder is cerebral autosomal
dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL), which is the most frequent
heritable cause of VaD. It results from mutations of the
NOTCH3 gene, mainly involving the cysteine residue, on
chromosome 19q12 that cluster in exons 3 and 4. Com-
mon manifestations are migraine headaches, recurrent
subcortical ischemic events, cognitive impairment, mood
disorders, and seizures [4]. This disorder has been the
subject of multiple reviews, and we refer to such an article
by Chabriat et al. for more information on CADASIL [4].
Another monogenic form, first described in 1989, is
Fabry disease (FD) an X-linked lysosomal disease due to
a mutation of the GLA gene (Xq22), resulting in an
absent or reduced a-galactosidase activity that finally
leads to accumulation of glycosphingolipid (globotriao-
silceramide) in different organs. Stroke or transient
ischemic attack, renal disease, and cardiomyopathy have
been observed in FD patients [5–7]. FD has been
described as a potential cause of young stroke (mostly
lacunar but also large vessel and cardioembolic) in 0.4–
11% of patients [8, 9].
Other more rarely described single-gene disease entities
are the COL4A1-A2 gene-related arteriopathy, which is a
possible cause of small vessel arteriopathy and intracranial
hemorrhages [10], and retinal vasculopathy with cerebral
leukodystrophy, which now subsumes three previously
considered separate entities (cerebroretinal vasculopathy,
hereditary endotheliopathy, retinopathy, nephropathy and
stroke, and hereditary vascular retinopathy). The typical
features of retinal vasculopathy with cerebral leukodystro-
phy are retinal vasculopathy, cognitive impairment,
migraine, psychiatric abnormalities, and seizures, as well
as hepatic and renal dysfunction [11, 12]. The disease is
due to the TREX1 gene and associated both with CSVD
neuroimaging features and, in some cases, pseudotumoral
lesions surrounded by vasogenic edema [13–15].
Finally, the cerebral autosomal recessive arteriopathy
with subcortical infarcts and leukoencephalopathy
(CARASIL), due to mutations in the HTA1 gene, has
been described in Asians and recently in some European
cases. Clinically, the disease is characterized by recurrent
lacunar strokes associated with a rapidly progressive
cognitive impairment, seizures, and psychiatrics disturb-
ance [16–20].
Although the above described single gene disorders
are believed to account for a small proportion of cases,
their prevalence is probably underestimated; systematic
studies on well-defined phenotypes and larger series are
needed since these diseases are expected to play a crucial
role in our understanding of the pathogenesis of VaD
and CSVD [21].
Sporadic vascular dementia
Compared to these monogenic forms, it is reasonable to
assume that sporadic VaD might have a more complex
mode of inheritance, in which multiple genetic variants
with small effects predispose to disease (similar to other
causes of dementia). Additionally, many of the risk
factors for VaD, such as hypertension, dyslipidemia, and
smoking habits, are partly genetically determined and
this may further complicate the picture [22]. Most of
our current genetic understanding of VaD is based on
candidate gene studies, while genome-wide associations
studies (GWAS) have so far only contributed modestly.
Candidate gene studies
The candidate genes for association studies may encom-
pass both genes implicated in stroke and Alzheimer
disease and genes that affect critical biological processes
to VaD. Given the multitude of candidate gene studies
and the common failure of replicating the findings, we
focus only on candidates that show consistent effect in
two or more published studies.
From a pathophysiological view, the genes involved in
lipid metabolism, especially the apolipoprotein E (APOE),
have been the focus of genetic research over the last two de-
cades. Several meta-analyses, including a recent one which
consists of 44 studies (2481 cases, 7490 controls), found a
significant association between ε4 allele carriers and in-
creased risk of VaD, irrespective of ethnicity [23–25]. How-
ever, there was no difference in risk for VaD between ε2 and
ε3 allele carriers nor in the APOE promoter T-427C [2].
Two polymorphisms (Q192R and L55M) of PON1 were as-
sociated with a higher risk of VaD in Indian and French
populations [26–28], but these findings for Q192R were not
confirmed in two other studies on European populations
[29, 30]. Several genes related to inflammation have also
been related to VaD, including two polymorphisms in the
TNF-α in Europeans [31] and Asians [32]. In addition, an
association between VaD and TGF-β1 was described in
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Table 1 Monogenic disorders associated with cerebral small vessel disease (modified from Bersano et al. [7])
Disease CADASIL Fabry disease RVCL COL4A1 CARASIL
OMIM #125310 #301500 #192315 #120130 #60142










Gene NOTCH3 α-GAL A gene (GLA) TREX1 COL4A1 HTRA1
Locus 19p13 Xq22 3p21.3-p21.2 13q34 10q25












Age at onset, years 20–70 33–46 (M)/40–52 (F) 40–50 14–49 20–40
Stroke subtype
Small vessel disease + + + + +
Large vessel disease – + – – –
Cardioembolic – + – – –
Hemorrhagic Rare Rare – + –
Other neurological manifestations
Psychiatric disturbance + + + + +
Migraine with/without aura + – + + –
Seizures + + +
Cognitive impairment + ± + + +
Extra-neurological manifestations
Neuropathy – + (80%) ± + –
Myopathy – – + + +
Renal disease – + + + –













Gastrointestinal involvement – + ± + –
Cardiac involvement – + – + –











White matter lesions + + + + +
Lacunar lesions + + + + +
Cortical-subcortical lesions – + ± – –
Intracerebral hemorrhage (ICH) + + – + +
Aneurysms – + – + –















in vascular endothelial cells











CADASIL cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, CARASIL cerebral autosomal recessive
arteriopathy with subcortical infarcts and leukoencephalopathy, RVCL retinal vasculopathy with cerebral leukodystrophy
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two Asian reports [33, 34]. Finally, the variant C677T of
methylenetetrahydrofolate-reductase (MTHFR), which
influences the level of homocysteine, was associated with
VaD in Asians in three meta-analyses [35–37], and more
recently also showing stronger evidence in Europeans
[25].
However, candidate gene studies have not identified
robust associations for various features of sporadic CSVD
such as lacunar infarction, intracerebral hemorrhage, or
white matter hyperintensities. Methodological issues,
particularly related to inaccurate or heterogeneous pheno-
typing and insufficient sample sizes, have been invoked as
possible reasons for this [6].
GWAS
To identify genetic risk factors for VaD, two GWAS have
been reported, firstly, a retrospective study in Koreans
(84 VaD patients, 200 controls) that did not detect any
genetic association [38], and a prospective study in the
Netherlands (67 patients, 5700 controls) that identified
an association with the variant rs12007229 near the
androgen receptor gene on the X chromosome, which
was replicated in a German population (221 cases, 213
controls) [39]. However, large-scale hypothesis-free studies
are lacking, thereby hampering gene discovery in VaD.
A more recent line of research has been to consider
genes that have been identified through GWAS of stroke
and AD. With respect to stroke, the Cohorts of the Heart
and Aging Research in Genetic Epidemiology (CHARGE)
consortium [40, 41], International Stroke Genetics Con-
sortium (ISGC) [42, 43], NINDS Stroke Genetics Network
(SiGN) [43], and Wellcome Trust Case Control Consor-
tium 2 (WTCCC2) [42] have conducted separate studies
totaling tens of thousands of stroke patients and hundreds
of thousands of controls. A variant near FOXF2 was found
to increase risk of all-stroke, and was also associated with
white matter hyperintensities. Furthermore, multiple ro-
bust associations have been reported in an apparent
subtype-specific manner – TSPAN2 was associated with
large artery atherosclerosis-related stroke, PITX2 and
ZFHX3 with cardioembolic stroke, HDAC9 with large ar-
tery atherosclerosis stroke, and ALDH2 with small artery
stroke. However, these genes have yet to be investigated
for their relation with VaD. Currently, even larger GWAS
on stroke are underway. Linking all these novel genes with
VaD would crucially advance our knowledge of its genetic
architecture. Similarly, the International Genomics of Alz-
heimer’s Project has identified various genes for AD
through GWAS [44], but these have yet to be associated
with VaD. Interestingly though, not all these novel genes
fit into known AD pathways involving amyloid or tau pro-
cessing [45]. Indeed, several genes have been implicated in
cardiometabolic pathways, most notably APOE, CLU, and
ABCA7, which are related to lipid metabolism [45].
In contrast to the candidate gene studies, GWAS have
recently been carried out successfully to identify novel
genes underlying CSVD. For white matter hyperintensi-
ties, for instance, five loci have been identified by studying
over 21,000 individuals from the CHARGE consortium
[46]. Interestingly, genes at these loci are implicated in
both AD and in (hemorrhagic) stroke [46]. Earlier findings
have been replicated in independent population-based
[47, 48] and clinical [49] samples. The CHARGE con-
sortium also investigated whether genetic influences
could be detected for the progression of white matter
hyperintensities over time [50]. While a very small
genetic contribution was identified, larger sample
sizes and improved methods for assessing change
could yield more results [50]. GWAS of MRI-defined
brain infarcts have been less robust, with an identified
association in the MACROD2 gene showing inconsist-
ent effects [51]. Nevertheless, whether the genetic
associations with CSVD can be effectively reflective of
those with VaD remains uncertain.
Instead of restricting genetic overlap to the top genes,
an exciting alternative approach is to test for genetic over-
lap between clinical endpoints on a genome-wide scale.
Novel methods, including linkage disequilibrium score
regression [52], now make such investigations possible.
Currently, a study is ongoing for stroke and AD and, if the
results are positive, this will provide important evidence of
a causal link between these two clinical distinct entities,
which overlap clinically in the realm of VaD.
Future developments
Despite the initial successes of GWAS, it is important to
keep in mind that the explained variance of these genetic
associations is limited, indicating that the largest propor-
tion of the heritability of CSVD still remains to be eluci-
dated. A common message from all genetic studies in the
field of VaD is that we need larger sample sizes. The gen-
etic complexity is such that there are likely thousands of
unknown variants, each with a modest contribution to
disease. Sufficient power can only be achieved by jointly
analyzing all data and will likely even necessitate cross-
consortia efforts. Furthermore, many consortia have
progressed to novel technologies, such as next generation
sequencing, which permit further identification of mul-
tiple causal variants, including rare variants [53].
Another important aspect of gaining power is by im-
proving phenotype definitions, which are currently quite
heterogeneous for VaD [54]. Further, mixed pathologies
are common above the age of 75 and require careful stat-
istical handling. While GWAS of clinical phenotypes has
started to provide robust association with current sample
sizes over hundreds of thousands of participants in VaD
and other complex diseases, the endophenotype approach
has shown promising results with much smaller sample
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sizes. The focus has so far been on white matter hyperin-
tensities and brain infarcts, but other neuroimaging traits
have yet to be analyzed. Particularly, brain microbleeds
(from T2*-weighted or susceptibility-weighted imaging),
enlarged perivascular spaces, and white matter integrity
(from diffusion imaging) would be important phenotypes
for VaD. Brain microbleeds and enlarged perivascular
spaces are markers for both ischemic and hemorrhagic
pathology [55, 56], and elucidating genetic factors that are
common to both pathways can also shed light on VaD.
Also, white matter integrity as measured by diffusion im-
aging provides a much more complete assessment of the
burden of CSVD, since it precedes many of the ‘end stage’
findings such as white matter hyperintensities [57].
Clinical implications of understanding the genetics of VaD
An important implication of unravelling the genetic
causes of VaD would be a biological understanding of its
origin. However, what genetic studies have actually
demonstrated so far is that clinical definitions are rather
heterogeneous; one of the primary challenges will be to
create robust definitions of VaD phenotypes, along with
the selection of appropriate controls and replication in
independent samples [58].
Understanding the causal genes and their underlying
disease mechanisms can also lead to the identification of
pathways. These can provide attractive targets for inter-
vention and subsequently stimulate drug development,
for which the related field of AD provides a good ex-
ample. The identification of causative mutations in APP,
PSEN1 and PSEN2 in familial AD cases has led to the
amyloid cascade hypothesis that changes in the APP
gene and its processing results in the aggregation and
deposition of amyloid-β, and this presumably leads to
disease. In GWAS of sporadic AD, the identification of
APOE (initially also through linkage) and, more recently,
a variety of other genes that are known to be implicated
in pathways such as immune response, endyctosis, and
lipid metabolism may lead to novel directions in drug
discovery [45].
Also, APOE is already used for the selection and strati-
fication of trial participants in drug development studies
for AD by using ε4 allele carriers as a high risk group.
The variability in the length of an intronic poly-T repeat
of the TOMM40, which is in linkage disequilibrium with
APOE on chromosome 19, has been shown to also have
a predictive value for disease risk [59], and an algorithm
combining both APOE and TOMM40 is now used in the
TOMMORROW randomized control trial [60]. The
identification of more genetic variants can thus lead to
improved selection of persons for clinical trials.
Furthermore, the variability of response to drugs among
individuals remains a key challenge of the pharmaceutical
drug research and in clinical practice, both in terms of
efficacy and adverse effects. This differential response of
individuals is thought to be related to genetic and non-
genetic factors. Pharmacogenetics (PGX) refers to the
inter-individual genome-wide DNA variations and poten-
tial interactions that correlate with drug response and tox-
icity [61]. With the addition of new omics translational
tools and technologies, the term now also encompasses
alterations in gene expression and post-translational
modifications (e.g., proteomics and metabolomics) that
also correlate with drug response and drug toxicity. PGX
studies are typically differentiated into two broad types,
namely safety PGX studies and efficacy PGX studies.
Safety PGX involves genes affecting drug absorption,
distribution, metabolism and excretion. Variations in these
genes may affect pharmacokinetic and pharmacodynamic
responses that may ultimately result into adverse effects.
Extensive sequencing data of such genes are increasingly
being used in various discovery stages by pharmaceutical
companies, as complementary tools of clinical pharmacol-
ogy databases for key decision-making processes. Efficacy
PGX includes studies involving genes that are known to
encode “druggable” targets. Variants within these genes
may affect target engagement, and thus alter efficacy. On
the other hand, disease susceptibility genes, identified
though large-scale GWAS analyses and meta-analyses on
cases and controls, serve for the generation of new discov-
ery hypotheses and for target validation, as well as for the
selection and/or stratification of patients in phase II
clinical trials. Ideally, assuming appropriate samples and
ethics approvals are in place for PGX and other biomarker
studies, positive efficacy signals may correlate with genetic
variants in responders to the active drug and not to the
placebo; these markers could then inform the much larger
(and considerably more expensive) phase III trials to
increase their probability of success through PGX/bio-
marker-enriched trial designs for the drug or several drugs
at a time. Such approaches have been successfully applied
in cancer, but regrettably not in most other therapy areas,
including vascular dementia.
Conclusions
Several genetic causes of monogenic forms of vascular
dementia have been documented, but their prevalence is
probably underestimated. Larger case series are needed to
further our understanding of the pathogenesis of VaD and
CSVD. For the sporadic form, there have been several
replicated candidate gene studies, but unbiased genome-
wide screens have remained underpowered and so far
yielded only few results. Future studies will need to be
larger, but could also improve power by harmonizing
phenotype definitions and studying endophenotypes. Thus
far, the clinical implications for VaD have been limited,
especially when compared to other diseases, but will hope-
fully follow after more robust genetic findings in the field.
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